Celon PharmaWAR:CLN -0.10%57 Gross Margin % is 70.67% as of Mar. 2026, which is 3% below its 10-year median of 72.95. GuruFocus rates WAR:CLN with a GF Score™ of 57/100 and a GF Value™ of zł22.61 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 935 Drug Manufacturers companies, Celon Pharma ranks better than 78.07% on this metric.
The historical rank and industry rank for Celon Pharma's Gross Margin % or its related term are showing as below:
WAR:CLN'
s Gross Margin % Range Over the Past 10 Years
Min: 58.95 Med: 72.95 Max: 77.88
Current: 66.32
During the past 11 years, the highestGross Margin % of Celon Pharma was 77.88%. The lowest was 58.95%. And the median was 72.95%.
WAR:CLN's Gross Margin % is ranked better than 78.07% of 935
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs WAR:CLN: 66.32
Celon Pharma had a gross margin of 70.67% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Celon Pharma was 0.00% per year.
Celon Pharma (WAR:CLN) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Celon Pharma had a gross margin of 70.67% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Celon Pharma Gross Margin % Related Terms
Celon Pharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for Celon Pharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:CLN vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Celon Pharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Celon Pharma (WAR:CLN) has a Gross Margin % of 70.67% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Celon Pharma and its competitors. This is near median its historical median of 72.95. Over the past decade, Celon Pharma's Gross Margin % has ranged from 58.95 to 77.88. According to the industry distribution chart, Celon Pharma ranks #205 out of 935 companies in the Drug Manufacturers industry, placing it in the top 21.9%.
Is Celon Pharma's Gross Margin % too high?
Celon Pharma's current Gross Margin % of 70.67% is near median its 10-year median of 72.95. Over the past 10 years, this metric has ranged from a low of 58.95 to a high of 77.88. The Drug Manufacturers industry median Gross Margin % is 48.54. Celon Pharma's value of 70.67% is 45.6% above this industry median. Based on the distribution chart, Celon Pharma ranks #205 out of 935 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Celon Pharma has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #205 out of 935 companies for Gross Margin %. This places Celon Pharma in the top 22% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Celon Pharma's value of 70.67% is 45.6% above this benchmark. Historically, Celon Pharma's own Gross Margin % has ranged from 58.95 to 77.88 over the past decade. While the company's 10-year median is 72.95 vs. the industry median of 48.54, Celon Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celon Pharma's current Gross Margin % of 70.67% is 45.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current Gross Margin % is 70.67%, which is near median its own 10-year median of 72.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł22.61, compared to a current price of zł19.84 — trading 12.3% below its estimated fair value. The current Gross Margin % is 70.67%, which is near median its 10-year median of 72.95 and 45.6% above the Drug Manufacturers industry median of 48.54. Celon Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Gross Margin % is 70.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celon Pharma (WAR:CLN) Overvalued in 2026?
Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued.
The current stock price of zł19.84 is trading 12.3% below its estimated GF Value™ of zł22.61.
GuruFocus considers Celon Pharma to be Modestly Undervalued.
Key valuation signals for WAR:CLN:
Gross Margin %: 70.67% (near median its 10-year median of 72.95)
GF Value™: zł22.61 vs. price of zł19.84 (12.3% below fair value)
Industry Position: 45.6% above the Drug Manufacturers median (#205 of 935)
No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
57GF Score
Get the complete analysis for WAR:CLN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CLN has been successfully added to your 
